Author | Year | N | Type of Study | Study Population (n) | Pre-TIPS Cr | Post-TIPS cr | Survival |
---|---|---|---|---|---|---|---|
Brensing [135] | 1997 | 16 | Prospective uncontrolled | HRS Type 1 & 2 | 2.57 ± 1.59 mg/dl | 1.18 ± 0.59 mg/dl | 56% |
Guevara [136] | 1998 | 7 | Prospective uncontrolled | HRS Type 1 | 5.0 ± 0.8 mg/dl | 1.8 ± 0.4 mg/dl | 28% Mean survival: 140 ± 68 days |
Brensing [137] | 2000 | 41 | Prospective | Non-TIPS (n = 10)HRS Type 1 (n = 7) HRS Type 2 (n = 3) | 2.3 ± 1.7 mg/dl | 1.5 ± 1.2 mg/dl | Mean Survival: TIPS: 92 ± 16 weeks Non TIPS: 12 ± 8.5 weeks |
 |  |  |  | TIPS (n = 31) HRS Type 1 (n = 14) HRS Type 2 (n = 17) |  |  | 3 month survival TIPS: 81% Non TIPS:10% |
Testino [138] | 2003 | 18 | Prospective uncontrolled | HRS Type 2 (n = 18) | 1.9 ± 0.5 mg/dl | 0.9 ± 0.3 mg/dl | 67%: Transplanted |